DALLAS, TX., November 17, 2009
ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP) today announced that a recommendation report was issued by ChangeWave, a research network that identifies emerging trends and companies best-positioned to capitalize in today’s marketplace. The report was written by Mr. Joshua Levine, Editor of ChangeWave Investing and ChangeWave MicroCap Investor.
According to Mr. Levine, “Finally, with MuGard now commercialized, Access is already receiving its first royalties, and cash flow will steadily ramp up in the coming quarters. Since MuGard has pharmaceutical-type margins, it will instantly impact Access’ financial situation. The increase in revenue will provide financial security for this company with an active partnering and outsourcing model and a very small $3 million-a-year burn rate.”
Read more »
European Launch Ongoing– Initial Clinician And Patient Feedback Very Positive
DALLAS, TX, November 11, 2009
ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), today provided an update on its North American commercial launch of MuGard, an FDA approved treatment for oral mucositis, a debilitating side effect of radiation treatment and chemotherapy. Access intends to commercially launch MuGard in North America in the first quarter of 2010. Key strategic items pertaining to the launch include:
• Manufacturing: Access is currently working with its contract liquid manufacturer, Accupac, on initial clinical and stability batches, and expects to have initial commercial quantities available in 1Q 2010.
• Reimbursement: Access is working with outside regulatory consultants in developing and finalizing its reimbursement strategy as it pertains to third-party payors and Medicare/Medicaid.
• Clinical: Consistent with strategies employed by its global marketing partners, Access is working with key opinion leaders to develop a strategy for post-approval studies if and as needed. Access believes that its approved label indication and directions for use supports positioning MuGard as a preventative for oral mucositis caused by radiation and chemotherapy treatments, and provides for expansion into treatment of all types of oral wounds including aphthous ulcers, canker sores and traumatic ulcers, such as those caused by oral surgery.
Read more »
Tweet
Digg!
Del.icio.us
Follow Us
Accesspharma: RT @